Cushing syndrome from percutaneous absorption of 1% hydrocortisone ointment in Netherton syndrome

Pediatric Dermatology

Volumn 24, Issue 1, 2007, Pages 42-45

  Halverstam, Caroline P ^b   Vachharajani, Akshaya ^b   Mallory, Susan Bayliss ^a,b  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE;

ARTICLE; CASE REPORT; CUSHING SYNDROME; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; LABORATORY TEST; MALE; NETHERTON DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCHOOL CHILD;

ADMINISTRATION, CUTANEOUS; ANTI-INFLAMMATORY AGENTS; CHILD; CUSHING SYNDROME; HUMANS; HYDROCORTISONE; MALE; MUTATION; OINTMENTS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PRURITUS; SKIN ABSORPTION; SKIN DISEASES, GENETIC; SYNDROME;

EID: 33846990435     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2007.00331.x     Document Type: Article

References (25)

1. Chavanas S, Bodemer C, Rochat A et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000;25:141-142.
2. Descargues P, Deraison C, Bonnart C et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat Genet 2005;37:56-65.
3. Feinblatt BI, Aceto T Jr, Beckhorn G et al. Percutaneous absorption of hydrocortisone in children. Am J Dis Child 1966;112:218-224.
4. Keipert JA, Kelly R. Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate. Med J Aust 1971;1:542-544.
5. Carruthers JA, August PJ, Staughton RCD. Observations on the systemic effect of topical clobetasol propionate (Dermovate). Br Med J 1975;4:203-204.
6. Borzyskowski M, Grant DB, Wells RS. Cushing's syndrome induced by topical steroids used for the treatment of non-bullous ichthyosiform erythroderma. Clin Exp Dermatol 1976;1:337-342.
7. Ruiz-Maldonado R, Zapata G, Tamayo L et al. Cushing's syndrome after topical application of corticosteroids. Am J Dis Child 1982;136:274-275.
8. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986;115:475-484.
9. Young CA, Williams IR, MacFarlane IA. Unrecognized Cushing's syndrome and adrenal suppression due to topical clobetasol propionate. Br J Clin Pract 1991;45:61-62.
10. Egelrud T, Brattsand M, Kreutzmann P et al. hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6 Br J Dermatol 2005;153:1200-1203.
11. Powell J, Dawber RPR, Ferguson DJP et al. Netherton's syndrome: increased likelihood of diagnosis by examining eyebrow hairs. Br J Dermatol 1999;141:544-546.
12. Ong C, O'Toole EA, Ghali L et al. LEKTI demonstratable by immunohistochemistry of the skin: a potential diagnostic skin test for Netherton syndrome. Br J Dermatol 2004;151:1253-1257.
13. Sprecher E, Tesfaye-Kedjela A, Ratajczak P et al. Deleterious mutations in SPINK5 in a patient with congenital ichthyosiform erythroderma: molecular testing as a helpful diagnostic tool for Netherton syndrome. Clin Exp Dermatol 2004;29:513-517.
14. Mueller FB, Hauber I, Berg D et al. Genetic analysis of a severe case of Netherton syndrome and application for prenatal testing. Br J Dermatol 2002;146:495-499.
15. Manabe M, Yoshiike T, Negi M et al. Successful therapy of ichthyosis linearis circumflexa with PUVA. J Am Acad Dermatol 1983;8:905-906.
16. Capezzera R, Venturini M, Bianchi D et al. UVA1 phototherapy of Netherton syndrome. Acta Derm Venereol 2004;84:69-94.
17. Wehr RF, Hickman J, Krochmal L. Effective treatment of Netherton's syndromewith 12% lactate lotion. J Am Acad Dermatol 1988;19:140-142.
18. Siegfried E, Nopper AJ, Draelos Z et al. Principles of treatment in pediatric dermatology. In: Schachner LA, Hansen RC, eds. Pediatric Dermatology. Edinburgh, New York: Mosby, 2003:87-148.
19. Happle R, van de Kerkhof PCM, Traupe H. Retinoids in disorders of keratinization: their use in adults. Dermatologica 1987;175:107-124.
20. Duperrat B, Puissant A, Blanchet-Bardon C et al. Syndrome de Netherton. Ann Derm Venereol 1977;104:568-569.
21. Coenraads PJ. Ichthyosis linearis circumflexa. Br J Dermatol 1980;102:484-485.
22. Godic A, Dragos V. Successful treatment of Netherton's syndrome with topical calcipotriol. Eur J Dermatol 2004;14:115-117.
23. Allen A, Siegfried E, Silverman R et al. Significant absorption of topical tacrolimus in 3 patients with Netherton Syndrome. Arch Dermatol 2001;137:747-750.
24. Bens G, Boralevi F, Buzenet C et al. Topical treatment of Netherton's syndrome with tacrolimus ointment without significant systemic absorption. Br J Dermatol 2003;149:224-225.
25. Rogers PJ, Wood SM, Garrett EL et al. Use of nonprescription topical steroids: patients' experiences. Br J Dermatol 2005;152:1193-1198.